Anti-βGal-hCD3

Notification: The cat. codes have been changed from bimab-bgalhcd3 and bimab-bgalhcd3-05 to bimab-bgcd3-01 and bimab-bgcd3-05. 

Anti-βGal-hCD3 binds to hCD3 on T cells but not to hCD19 on B cells

Monoclonal scFv antibody against β-galactosidase and human CD3; Negative control

Anti-βGal-hCD3 is a bispecific antibody that binds to two sites: E. coli β-galactosidase (β-Gal)and hCD3, part of the T cell receptor. It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, alike Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].

References:

1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.

Figures

A. Evaluation of T cell activation. Raji cells were pre-incubated with Anti-hCD19-CD3, or the two bispecific negative controls Anti-β-Gal-hCD3 and Anti-hCD19-β-Gal for 30 minutes before addition of Jurkat-Lucia™ NFAT cells. After 8 hours incubation, T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ detection reagent. Results are presented as relative activity expressed as a percentage of Lucia activity in samples with the highest dose of antibody.
B. Target specificity of Anti-hCD19-CD3 was verified upon incubation with Jurkat-Lucia™ NFAT cells and Raji cells as described in (A), with Jurkat-Lucia™ NFAT cells only, or with Raji cells only. T cell activation was determined by measuring the Lucia luciferase activity using QUANTI-Luc™ and expressed as relative light units (RLUs).

Specifications

Clonality: Monoclonal antibody.

Specificity: E. coli β-galactosidase (β-Gal) and human CD3.

Isotype: none (scFv).

Source: CHO (Chinese hamster ovary) cells.

Purity: >90%. Purified by affinity chromatography.

Quality control:

•    Binding to hCD3 has been confirmed by flow cytometry.
•    The inability of Anti-βGal-hCD3 to induce T cell activation has been confirmed using cellular assays.
•    The complete sequence of this antibody has been verified.
•    The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

Contents

Anti-βGal-hCD3 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• bimab-bgcd3-01: 10 µg
• bimab-bgcd3-05: 5 x 10 µg

Product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20°C.